Loss of smell in Alzheimer’s disease is both well-documented and poorly understood. Research consistently shows that people with Alzheimer’s experience reduced ability to detect, identify, and discriminate odors—often in the early stages of the disease, sometimes before memory loss becomes obvious. A person with early Alzheimer’s might pass a loved one’s perfume without recognition, or fail to notice burnt food on the stove, changes that happen gradually enough that family members sometimes don’t realize what’s occurring until the decline is already significant. However, the relationship between olfactory loss and Alzheimer’s is not straightforward, and it carries real limits.
Smell loss alone cannot diagnose Alzheimer’s disease. Many conditions cause smell problems—Parkinson’s disease, normal aging, chronic sinusitis, COVID-19, and certain medications all affect the olfactory system. The neurological mechanisms linking smell loss to Alzheimer’s pathology are still being mapped. Researchers know that amyloid-beta and tau proteins accumulate in brain regions controlling smell, but they’re still working to understand exactly how and why this happens first in the olfactory system, and whether stopping smell loss would slow cognitive decline.
Table of Contents
- How Common is Smell Loss in Alzheimer’s Disease?
- What the Research Evidence Shows About Olfactory Changes
- Why Does Alzheimer’s Affect the Sense of Smell?
- Detecting Smell Loss Early: What Caregivers Should Watch For
- Limitations of Smell Tests as an Alzheimer’s Indicator
- How Smell Loss Differs from Other Sensory Changes in Dementia
- The Olfactory Bulb and Alzheimer’s Pathology
How Common is Smell Loss in Alzheimer’s Disease?
Olfactory dysfunction occurs in roughly 70 to 90 percent of people with Alzheimer’s disease, according to multiple research studies. This rate is notably higher than in age-matched control groups without dementia, where smell problems affect perhaps 10 to 20 percent of people. The loss typically manifests as anosmia (complete inability to smell) or hyposmia (reduced smell sensitivity), and in many cases it appears before cognitive symptoms are severe enough to prompt a medical evaluation. The timeline matters. Studies suggest that smell loss can be detected in mild cognitive impairment (MCI)—the intermediate stage between normal aging and dementia—and even earlier. Some research has found olfactory deficits in people who show no cognitive symptoms but do show Alzheimer’s-related brain changes on imaging or biomarkers in cerebrospinal fluid.
This raises a tantalizing possibility: perhaps smell testing could identify people at risk years before memory loss becomes obvious. Yet this remains unproven clinically. No major health organization currently recommends smell tests as a screening tool for Alzheimer’s in asymptomatic people. Older adults themselves often underestimate their smell loss. In one study, people reported normal smell function while objective testing revealed significant deficits. This gap between perception and reality means that a family member’s complaint about smell loss should not be dismissed as paranoia or exaggeration—careful observation can reveal true impairment that the person hasn’t consciously noticed or reported.
What the Research Evidence Shows About Olfactory Changes
The evidence linking Alzheimer’s pathology to smell loss centers on specific brain structures. The olfactory bulb—the small neural region that processes smell signals from the nose—shows some of the earliest accumulation of amyloid-beta and tau proteins in Alzheimer’s disease. Neurons in the olfactory cortex, piriform cortex, and entorhinal cortex all show degeneration. Autopsy studies confirm this pattern. A person with Alzheimer’s often has severe pathological changes in olfactory brain regions even when other parts of the cortex show less damage. However, this anatomical correlation does not prove causation. Some older adults show significant Alzheimer’s pathology in the olfactory bulb without ever developing dementia—they died of other causes first.
Others have severe dementia with relatively spared olfactory regions. The relationship is strong enough to be clinically relevant but loose enough that smell loss alone cannot predict who will progress to dementia. Additionally, olfactory dysfunction in Alzheimer’s likely involves both the central nervous system (the brain regions processing smell) and peripheral changes in the olfactory epithelium (the tissues lining the nasal cavity that first detect odors). Teasing apart which component drives the loss remains an active research question. One significant limitation is that most olfactory research in Alzheimer’s comes from North American and European populations. Whether smell loss patterns are similar across different genetic backgrounds and environments remains understudied. Cultural differences in diet, air quality, smoking rates, and past infections (all of which affect the olfactory system) mean that smell loss may manifest differently in other populations.
Why Does Alzheimer’s Affect the Sense of Smell?
The olfactory system has a unique direct line to the brain. Olfactory neurons in the nasal epithelium make physical contact with the olfactory bulb at the base of the brain—they are among the only neurons that directly touch the outside world. This proximity means that whatever pathological processes drive Alzheimer’s disease may reach the olfactory system early and easily. Some researchers have hypothesized that infectious agents, environmental toxins, or misfolded proteins might enter the brain via the olfactory pathway, though this remains speculative. Another mechanism involves neuroinflammation. Alzheimer’s disease involves chronic activation of microglia and astrocytes—immune cells in the brain—that release inflammatory molecules.
The olfactory bulb may be particularly vulnerable to these inflammatory changes. In animal models of Alzheimer’s, olfactory neurons show signs of oxidative stress and mitochondrial dysfunction. A person with Alzheimer’s might lose smell partly because the neurons processing odor signals are being damaged by the same inflammatory and toxic processes harming memory circuits elsewhere in the brain. There is also evidence that Alzheimer’s impairs not just the detection of smell but the cognitive processing of it. Even when a person can technically detect an odor, they may fail to identify it—asked to smell coffee, they don’t recognize it as coffee. This suggests damage extends beyond the initial sensory detection to higher brain regions involved in semantic memory (knowing what things are called and what they mean). A caregiver might notice that a person with Alzheimer’s walks past fresh-baked bread and shows no reaction, or that they cannot identify common household smells like lemon or mint when tested formally, even though their olfactory sensory organs are still technically functional.
Detecting Smell Loss Early: What Caregivers Should Watch For
Clinical smell tests exist and can objectively measure olfactory dysfunction. The University of Pennsylvania Smell Identification Test (UPSIT) is the most widely used. It contains 40 scratch-and-sniff items; people with Alzheimer’s typically score significantly below healthy older adults. The Brief Smell Identification Test (BSIT) is a shorter 12-item version. Threshold tests measure the lowest concentration of an odor a person can detect. However, these tests require special equipment, trained administration, and are not routinely done outside of research or specialized clinics. Most early-stage smell loss in Alzheimer’s is detected through everyday observation, not formal testing. A family member might notice that the person no longer comments on food aromas, or that they seem indifferent to smells they once loved—a parent who adored coffee no longer registers it in the morning, a spouse who enjoyed perfume now ignores it.
Some people burn food more often or leave the stove on, suggesting they cannot smell smoke or hot metal. Others stop enjoying meals not from taste loss (which is less common in early Alzheimer’s) but from loss of aroma, which contributes heavily to flavor perception. The challenge is distinguishing Alzheimer’s-related smell loss from other causes. A person with chronic sinusitis or nasal polyps might lose smell. Medications—anticholinergics, beta-blockers, and others—can impair olfaction. A recent upper respiratory infection can temporarily damage the olfactory epithelium. Normal aging itself causes mild smell decline. If a family member notices new smell loss, it warrants a medical evaluation, but the evaluation should include a full history and possibly imaging or bloodwork before attributing it specifically to Alzheimer’s.
Limitations of Smell Tests as an Alzheimer’s Indicator
A major limitation is specificity. Smell loss is not unique to Alzheimer’s. Parkinson’s disease also causes olfactory dysfunction, often early and severe—sometimes earlier than motor symptoms. Lewy body dementia impairs smell. Frontotemporal dementia may or may not. Vascular dementia and normal aging do so as well. If someone has smell loss, many possible explanations exist, and Alzheimer’s is just one of them. A positive smell test result does not point to a specific diagnosis. Sensitivity is another issue.
While many people with Alzheimer’s have smell loss, not all do. Some individuals with confirmed Alzheimer’s pathology (verified by biomarkers or autopsy) retain relatively normal olfactory function. This means that a normal smell test cannot rule out Alzheimer’s. Conversely, some older adults without any cognitive impairment show smell loss equivalent to people with dementia—smell dysfunction alone is not a red flag that dementia is necessarily present or imminent. There is also a practical limitation: smell tests are not widely available outside of research settings or specialized medical centers. Most primary care physicians do not have smell-testing equipment in their office. A family member worried about a loved one’s cognition cannot walk into a typical clinic and request a smell evaluation. This means that in clinical practice, smell loss tends to be noticed incidentally (during history-taking for another problem) rather than systematically screened. By the time smell loss prompts a medical visit, cognitive changes may already be significant.
How Smell Loss Differs from Other Sensory Changes in Dementia
Unlike taste, which declines in Alzheimer’s much less commonly and usually more mildly, smell loss is often profound. A person with Alzheimer’s might still enjoy sweet, salty, sour, and bitter tastes but cannot smell food—making meals taste bland. The distinction is important because family members sometimes assume the person no longer wants to eat because they’ve lost taste, when actually the loss of aroma (which creates most of what we experience as flavor) is the culprit. Offering strongly flavored foods or adding spices sometimes helps.
Hearing loss in Alzheimer’s is common but generally reflects normal age-related decline rather than a specific part of the disease process. Vision loss, similarly, is typical in aging but not particularly specific to Alzheimer’s. Smell loss, by contrast, appears to be a relatively specific marker of Alzheimer’s pathology, showing up earlier and more dramatically than other sensory losses and correlating with amyloid-beta accumulation in the olfactory system. This relative specificity is why researchers have been interested in smell as a potential early-detection biomarker, even though it remains unproven clinically.
The Olfactory Bulb and Alzheimer’s Pathology
The olfactory bulb is one of the smallest structures in the brain, weighing less than a gram, yet it receives direct input from thousands of olfactory neurons in the nose. In Alzheimer’s disease, the olfactory bulb often shows some of the densest deposits of amyloid-beta and tau. Autopsies of people with Alzheimer’s regularly reveal severe neurodegeneration in the olfactory bulb long before equivalent damage appears in the hippocampus or other memory centers. This anatomical fact has led some researchers to propose that Alzheimer’s pathology originates or early propagates through the olfactory system, though this “olfactory entry hypothesis” remains unproven.
What is certain is that early pathological changes in the olfactory bulb correlate with cognitive decline measured years later. Studies following people over time have shown that worse olfactory scores in baseline testing predict greater cognitive decline or earlier dementia diagnosis at follow-up—a relationship stronger than many other biomarkers. Yet knowing this does not yet translate to clinical tools. No drug or intervention targeting the olfactory system has been shown to slow Alzheimer’s progression, and no clinical guideline recommends smell testing as part of Alzheimer’s screening or diagnosis.
- —
